Cancer immunotherapy companies
Companies whose enriched business profile is tagged “Cancer immunotherapy”, drawn from their SEC filings + website text. Sorted by market capitalization; every figure is delayed data from SEC EDGAR + Finnhub, shown with its as-of date.
- Bristol Myers Squibb (BMY) Health Care — A diversified biopharmaceutical company leveraging immunotherapy, cell therapies, and small-molecule platforms to address cancer, autoimmune disease, and specialty care. ask →
- IMMUNITYBIO INC (IBRX) Health Care — ImmunityBio develops engineered natural killer cell and cancer vaccine therapies, led by its approved ANKTIVA treatment for bladder and lung cancers, to harness the immune system against cancer and infectious diseases. ask →
- ARCUS BIOSCIENCES INC (RCUS) Health Care — A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in late-stage trials. ask →
- NEKTAR THERAPEUTICS (NKTR) Health Care — Clinical-stage immunotherapy company developing regulatory T cell-targeted treatments for autoimmune diseases and cancer. ask →
- VIR BIOTECHNOLOGY INC (VIR) Health Care — Vir Biotechnology develops novel immunology-driven therapeutics targeting infectious diseases and cancer using proprietary T-cell engagement and masking technologies. ask →
- CANDEL THERAPEUTICS INC (CADL) Health Care — Clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies to trigger systemic anti-tumor immune responses by inducing immunogenic cell death within solid tumors. ask →
- COMPASS THERAPEUTICS (CMPX) Health Care — Clinical-stage biotech company developing proprietary bispecific and agonistic antibodies targeting angiogenesis, immune checkpoints, and tumor microenvironment for solid tumor cancers. ask →
- PERSPECTIVE THERAPEUTICS INC (CATX) Health Care — A targeted alpha therapy biotech advancing novel oncology candidates through clinical development toward potential FDA approval and commercialization. ask →
- LYELL IMMUNOPHARMA INC (LYEL) Health Care — Late-stage clinical cell therapy company engineering next-generation dual-targeting CD19/CD20 CAR T-cell therapies for blood cancers and solid tumors, with a lead program in pivotal trials and an in-house manufacturing facility. ask →
- PROTARA THERAPEUTICS INC (TARA) Health Care — Clinical-stage biopharmaceutical company developing TARA-002, a cell therapy based on an established immunopotentiator, and IV Choline Chloride for oncology, rare diseases, and nutritional support. ask →
- AGENUS INC (AGEN) Health Care — A clinical-stage immuno-oncology company advancing checkpoint immunotherapy and combination therapies, primarily botensilimab, while generating near-term revenue through royalty sales and partnerships. ask →
Not quite it? Describe exactly what you want →
Data: SEC EDGAR (filings) + Finnhub (fundamentals, delayed daily-close). Figures shown with their as-of date.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.